Brevan Howard Capital Management LP Igm Biosciences, Inc. Transaction History
Brevan Howard Capital Management LP
- $12.7 Billion
- Q1 2024
A detailed history of Brevan Howard Capital Management LP transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 10,589 shares of IGMS stock, worth $66,498. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,589
Previous 11,877
10.84%
Holding current value
$66,498
Previous $98,000
4.08%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding IGMS
# of Institutions
89Shares Held
20.5MCall Options Held
11.1KPut Options Held
5.1K-
Baker Bros. Advisors LP New York, NY4.09MShares$25.7 Million0.5% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.89MShares$24.4 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N43.08MShares$19.3 Million1.6% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$19.3 Million1.17% of portfolio
-
Goldman Sachs Group Inc New York, NY1.28MShares$8.03 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $182M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...